Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018

By George Budwell - Updated Apr 19, 2019 at 11:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bristol's inability to compete against Merck in front-line lung cancer weighed heavily on its shares last year.

What happened

Biopharma heavyweight Bristol-Myers Squibb ( BMY 0.84% ) saw its shares sink by a staggering 15.2% in 2018, according to data from S&P Global Market Intelligence. What caused investors to hit the exits last year?

While biopharma stocks in general performed rather poorly in 2018 due to a bevy of headwinds, Bristol's stock was particularly hard hit due to its star immuno-oncology drug, Opdivo, losing significant ground to Merck's ( MRK -0.74% ) Keytruda over the course of the year.   

A doctor inspecting an x-ray of a patient with lung cancer.

Image source: Getty Images.

So what

The long and short of it is that Merck's Keytruda was able to solidify its already-dominant position in untreated lung cancer during 2018. The net result -- and the issue that seems to  have weighed most heavily on Bristol's shares last year -- is that Keytruda's win in front-line lung cancer should allow to it generate nearly $2 billion a year more in sales than Opdivo once these drugs reach their commercial peaks in the next five years, according to a report by EvaluatePharma. Two short years ago, though, industry insiders widely believed the opposite would be the case.      

Now what

With Merck taking the pole position in first-line lung cancer with Keytruda last year, Bristol decided to kick off 2019 with the massive acquisition of cancer specialist Celgene Corporation ( CELG ). This megamerger -- if it proceeds as planned -- would instantly transform Bristol into a top dog in the high-value oncology space. Celgene, after all, sports a rich pipeline of anti-cancer therapies, including next-generation product candidates such as bb2121 and liso-cel. 

That said, there are concerns that regulators might nix this deal -- or perhaps force some key asset divestitures -- over drug pricing concerns. As such, Bristol's stock may continue to struggle until this proposed megamerger actually comes to fruition.

Check out the latest Bristol-Myers Squibb earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$55.41 (0.84%) $0.46
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$73.89 (-0.74%) $0.55
Celgene Corporation Stock Quote
Celgene Corporation
CELG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.